In Situ-Crosslinked Zippersomes Enhance Cardiac Repair by Increasing Accumulation and Retention

Natalie E. Jasiewicz,Kuo-Ching Mei,Hannah M. Oh,Emily E. Bonacquisti,Ameya Chaudhari,Camryn Byrum,Brian C. Jensen,Juliane Nguyen
DOI: https://doi.org/10.1101/2024.03.14.585030
2024-03-16
Abstract:Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) are a promising treatment for myocardial infarction, but their therapeutic efficacy is limited by inefficient accumulation at the target site. A non-invasive MSC EV therapy that enhances EV accumulation at the disease site and extends EV retention could significantly improve post-infarct cardiac regeneration. Here we show that EVs decorated with the next-generation of high-affinity heterodimerizing leucine zippers, termed high-affinity (HiA) Zippersomes, amplify targetable surface areas through in situ crosslinking and exhibited ∼7-fold enhanced accumulation within the infarcted myocardium in mice after three days and continued to be retained up to day 21, surpassing the performance of unmodified EVs. After myocardial infarction in mice, high-affinity Zippersomes increase the ejection fraction by 53% and 100% compared with unmodified EVs and PBS, respectively. This notable improvement in cardiac function played a crucial role in restoring healthy heart performance. High-affinity Zippersomes also robustly decrease infarct size by 52% and 60% compared with unmodified EVs and PBS, respectively, thus representing a promising platform for non-invasive vesicle delivery to the infarcted heart.
Bioengineering
What problem does this paper attempt to address?
The problem that this paper attempts to solve is that in the treatment of myocardial infarction, extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) have limited therapeutic effects due to insufficient accumulation at the target site and short retention time. The research team has developed a non - invasive MSC - EV therapy, which significantly improves the cardiac regeneration ability after myocardial infarction by enhancing the accumulation of EVs at the disease site and prolonging the retention time. Specifically, the researchers designed a new generation of EVs named high - affinity (HiA) Zippersomes. These EVs are decorated on the surface with high - affinity heterodimerized leucine zipper proteins, which can cross - link in situ in vivo, thereby increasing the accessible surface area in the target area and showing an enhanced accumulation of about 7 - fold in the infarcted myocardium of mice and can still be continuously retained on the 21st day. Compared with unmodified EVs and phosphate - buffered saline (PBS), HiA Zippersomes can significantly increase the cardiac ejection fraction (by 53% and 100% respectively) and greatly reduce the infarct area (by 52% and 60% respectively), thus representing a promising non - invasive vesicle delivery platform for the treatment of myocardial infarction.